<DOC>
	<DOCNO>NCT02293850</DOCNO>
	<brief_summary>This open label , multiple center , two country ( Taiwan Korea ) non-comparative phase I/II trial patient hepatocellular carcinoma . In phase I part , maximum 33 patient recruit study . By utilize Simon optimal two-stage design , 69 patient enrol study , consider 20 % drop-out rate , order target 19 response-evaluable patient first stage additional 36 response-evaluable patient second stage phase II part study .</brief_summary>
	<brief_title>Phase I/II Study Evaluate Safety Efficacy Telomelysin ( OBP-301 ) Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description>After screen , eligible patient undergo treatment OBP-301 within 14 day automatically enter follow-up period . The follow-up period 12 week last injection phase I part , 24 week last injection phase II part . Each patient return follow-up visit weekly first month last injection , every 4 week end follow-up period phase .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . Patients age 18 65 year ( 19 65 year Korea ) phase I part age 18 75 year ( 19 75 year Korea ) phase II part , either sex 2 . Patients diagnose hepatocellular carcinoma . The diagnosis HCC ( hepatocellular carcinoma ) establish cytology histopathology 3 . Patients unresectable HCC meet follow condition : Barcelona Clinic Liver Cancer ( BCLC ) stage B C TransAarterial ChemoEmbolization ( TACE ) refractory discretion investigator , TACE unsuitable ( limited portal vein thrombosis ) Local ablative treatment ( percutaneous ethanol injection , radiofrequency ablation , etc ) unsuitable Sorafenib failure , intolerable ineligible 4 . Patients must least one lesion accurately measure least one dimension 1 cm lesion must suitable repeat measurement 5 . Patients ChildPugh 's Score great 7 , ascites 6 . Patients condition screen : serum ALT ( Alanine Aminotransferase ) level ( GPT ) less 2.5 x UNL serum AST ( Aspartate Aminotransferase ) level ( GOT ) less 2.5 x UNL WBC ( white blood cell ) great equal 3,000 / microliter Serum creatinine less equal 1.5 x UNL activate partial thromboplastin time ( APTT ) &lt; 1.5 x UNL 7 . Platelet count correctable great equal 80,000 / microliter 8. prothrombin timeinternational normalize ratio ( PTINR ) correctable le 1.5 9 . Patients life expectancy longer 12 week 1 . Patients chemotherapy within last three week ( 6 week nitrosourea MitomycinC ) prior dose 2 . Patients radiotherapy tumor site within last four week prior dose documentation subsequent tumor growth site 3 . Patients receive investigational antineoplastic medication within last four week prior dose 4 . Patients history esophageal variceal bleeding within eight week prior study entry 5 . Patients uncontrolled diabetes , active chronic infection , include HIV , except asymptomatic bacterial colonization , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) infection 6 . Patients acute viral infection syndrome diagnose within last two week 7 . Patients concomitant hematological malignancy ( e.g . acute lymphocytic leukemia , nonHodgkin 's lymphoma ) 8 . Patients active rheumatoid arthritis autoimmune disease . 9 . Patients current requirement chronic systemic immunosuppressive medication include dose glucocorticoid cyclosporin , chronic use medication within last four week Note : Course glucocorticoid therapy le 10 day duration allow ( e.g . nausea control ) 10 . Patients organ transplant ( may require prolonged immunosuppressive therapy ) 11 . Patients prior participation research protocol involve administration adenovirus vector 12 . Patients receive immunerelated related relate related relate blood product , immunoglobulin prior 3 month 13 . Patients uncontrolled concurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement 14 . Psychiatric , addictive , disorder compromise ability give truly informed consent participation study adequate compliance 15 . Female patient pregnant breastfeed 16 . Patients receive antiplatelet agent anticoagulation agent ( e.g . Heparin , warfarin , aspirin , ticlopidine , clopidogrel , dipyridamole ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>